Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
|
US |
|
Ganesh Housing Corp Ltd
NSE:GANESHHOUC
|
IN |
|
Frasers Logistics & Commercial Trust
SGX:BUOU
|
SG |
|
Fenix Outdoor International AG
STO:FOI B
|
CH |
|
S
|
Solid Stone Co Ltd
BSE:513699
|
IN |
|
Envirosuite Ltd
ASX:EVS
|
AU |
|
Eagle High Plantations Tbk PT
IDX:BWPT
|
ID |
|
Tejas Networks Ltd
NSE:TEJASNET
|
IN |
|
EROAD Ltd
NZX:ERD
|
NZ |
|
R
|
RVRC Holding AB
STO:RVRC
|
SE |
|
Check Point Software Technologies Ltd
NASDAQ:CHKP
|
IL |
|
N
|
NCR Atleos Corp
NYSE:NATL
|
US |
|
G
|
Greatland Resources Ltd
SWB:U0Y
|
AU |
|
JCDecaux SA
OTC:JCDXF
|
FR |
|
Genomic Vision SA
PAR:GV
|
FR |
|
E
|
Erayak Power Solution Group Inc
NASDAQ:RAYA
|
CN |
|
Primo Water Corp
TSX:PRMW
|
US |
Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 5 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops and seeks to commercialize therapeutics for various diseases. Its pipeline focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics driven technology platform and chemistry to develop new medicines. Its pipeline has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Its primary focus is developing its lead product candidate, RP5063, for the treatment of schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), behavioral and psychotic symptoms, dementia or Alzheimer's disease (BPSD), Parkinson's disease psychosis (PDP), and attention deficit hyperactivity disorder (ADHD). RP5063 also focuses on the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The firm's RP1208, is in pre-clinical development, which focuses on the treatment of depression and obesity.
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 5 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops and seeks to commercialize therapeutics for various diseases. Its pipeline focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics driven technology platform and chemistry to develop new medicines. Its pipeline has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Its primary focus is developing its lead product candidate, RP5063, for the treatment of schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), behavioral and psychotic symptoms, dementia or Alzheimer's disease (BPSD), Parkinson's disease psychosis (PDP), and attention deficit hyperactivity disorder (ADHD). RP5063 also focuses on the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The firm's RP1208, is in pre-clinical development, which focuses on the treatment of depression and obesity.
